ReviewOncology letters2026
Progress in the treatment of esophageal neuroendocrine carcinoma (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Esophageal NEN: update on diagnostics and surgical treatment].Chirurgie (Heidelberg, Germany) · 2026Review
- Esophageal neuroendocrine carcinoma: molecular insights, diagnostic advances, and emerging treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal neuroendocrine carcinoma (ENEC) is a rare and highly aggressive gastrointestinal malignancy with a markedly worse prognosis compared with other pathological types of esophageal cancer. The present study aimed to provide a systematic review of the pathological features, diagnostic strategies and advances in stratified treatment of ENEC, with a focus on current therapeutic approaches. The management of ENEC requires a multimodal approach. Among these modalities, surgery remains the cornerstone for achieving long-term survival. For patients with initially unresectable disease, neoadjuvant therapy can convert cases to a resectable status. Additionally, combined chemoradiotherapy has been demonstrated to markedly improve survival rates. Beyond conventional treatments, the potential of targeted therapy in combination with chemotherapy has been suggested, and the synergy between immune checkpoint inhibitors and either radiotherapy or targeted drugs has achieved long-term remission in certain cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.